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Stlmmal-y 
To test whether the product of the bcl-2 proto-oncogene blocks clonal deletion of self-reactive 
B cells, we have generated transgenic mice carrying the bcl-2 gene and the immunoglobulin genes 
for the anti-erthrocyte 4C8 antibody. In these transgenic mice, donal deletion of self-reactive 
immature B cells in the bone marrow was not inhibited in spite of expression of the bcl-2 gene. 
In contrast, self-antigen-induced donal deletion of mature self-reactive Ly-1 B (B1) cells in the 
peritoneal cavity was inhibited in the transgenic mice. These results indicate that the mechanism 
for clonal deletion of immature self-reactive B cells in the bone marrow differs  from that of 
mature self-reactive B cells in the periphery. 
I 
g V gene diversity is amplified by somatic DNA rearrange- 
. ment in B cell precursors of the bone marrow and fetal 
liver, and by somatic mutations in mature B cells of the pe- 
ripheral  lymphoid organs.  Such amplification of diversity 
allows the immune system to react with almost all possible 
foreign antigens. The Ig repertoire amplified by genetic mech- 
anisms, includes Ig reactive to self as well as foreign antigens 
and thus, without appropriate selection, self-reactive B cells 
inevitably emerge. 
Studies on autoantibody transgenic mice (1-5) have clearly 
demonstrated that self-reactive B cells are surveyed by mul- 
tiple mechanisms of immunological tolerance (6-8). Soluble 
self-antigens render self-reactive B cells to an inactive state, 
in which B cells fail to respond to the stimulation by an- 
tigens and T helper cells (clonal anergy). Membrane-bound 
self-antigens eliminate self-reactive B cells presumably by strong 
cross-linking of surface Ig (slg) 1 receptors (donal deletion). 
In transgenic mice which produce autoantibodies reactive to 
self-antigens expressed in the bone marrow, both bone marrow 
and peripheral B cells are tolerized by either anergy or dele- 
tion, suggesting that the bone marrow immature B cells may 
be the major target of the B cell tolerance (1, 3, 5). However, 
the transfer experiment of mature self-reactive B cells into 
mice producing self-antigens revealed that mature B cells can 
be also anergized (1). Since self-antigens in the liver elimi- 
1 Abbreviations used in this paper: Ht, hematocrit; MFI, mean fluorescence 
intensities; NP, 4-(hydroxy-3-nitrophenyl)acetyl; slg, surface Ig. 
nated self-reactive B cells in the periphery but not in the bone 
marrow (9), clonal deletion also appears to take place at some 
stage after B cells migrate from the bone marrow to the pe- 
riphery. 
We have analyzed a transgenic mouse line expressing both 
H  and L chains of the 4C8 antierythrocyte autoantibody in 
almost all the B cells (5).  As is the case for other autoanti- 
body transgenic mice (1, 3),  the number of B cells in the 
bone marrow, spleen, and lymph nodes in these transgenic 
mice are markedly reduced most likely because of clonal de- 
letion at the immature B cell stage in the bone marrow by 
interaction with RBCs and/or their precursors. However, ma- 
ture Ly-1 B cells reacting to RBCs are found in the perito- 
neal cavity presumably because the peritoneal cavity is se- 
questered from self-antigens (RBCs). These mature Ly-1 B 
cells undergo apoptotic cell death upon intraperitoneal injec- 
tion of RBCs (10).  Thus, both immature bone marrow B 
cells and mature Ly-1 B cells are eliminated by interaction 
with the self-antigens in these mice. 
Accumulating evidence suggests that bone marrow imma- 
ture B cells and peripheral mature B cells are functionally 
distinct.  Immature B cells do not respond to cross-linking 
of the slg in vitro, whereas the same stimulation induces DNA 
synthesis in mature B cells (11). Further evidence comes from 
the observation that slg-associated molecules and signal trans- 
duction pathways via slg receptor complexes are different in 
immature and mature B cells (12).  In spite of these differ- 
ences, no data refer to distinct tolerance mechanisms between 
B cells in the bone marrow and the periphery. 
The bcl-2 proto-oncogene was found as a result of its trans- 
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center B cell lymphomas (13). The bcl-2 gene product has 
been shown to delay the onset of apoptotic cell death in cer- 
tain hematopoietic cell lines deprived of growth factors (14-17). 
Besides  the inhibition of apoptosis in these cell lines,  the 
bd-2 gene product also inhibits apoptosis of normal lym- 
phocytes. Indeed, Strasser et al. (18) and Sentman et al. (19) 
found that anti-CD3 antibody-induced apoptosis of imma- 
ture thymocytes was inhibited in bcl-2 transgenic mice. These 
transgenic mice, however,  showed little, if any, abrogation 
of clonal deletion of T  cells reactive  to self-superantigens, 
suggesting that self-tolerance is maintained by multiple mech- 
anisms,  some of which are not perturbed by bcl-2. 
To assess whether bcl-2 inhibits elimination of self-reactive 
B cells in both the periphery and the bone marrow, we ana- 
lyzed antigen-induced elimination of peripheral Ly-1 B cells 
and clonal deletion of immature B cells in the bone marrow 
in transgenic mice carrying the genes for bcl-2 and the an- 
tierythrocyte  antibody. The data shown here demonstrate that 
the bcl-2 gene product inhibits clonal deletion of peritoneal 
Ly-1 B cells but not that of bone marrow immature B cells, 
suggesting that distinct mechanisms are  involved in  self- 
tolerance of B lymphocytes in central and peripheral lym- 
phatic organs. 
Materials  and Methods 
Transgenic Mice.  The transgenic mouse lines carrying either Ig 
/~ or L chain gene for antierythrocyte antibody (4C8 mAb) were 
established as described by Okamoto et al. (5) and maintained in 
our animal colony. The El~-bcl-2 transgenic line was kindly donated 
by Dr. A. Strasser (18). The transgenic line carrying # chain gene 
for anti-(4-hydroxy-3-nitrophenyl)acetyl  (NP) antibody was kindly 
donated by Drs. T. Era and S.-I. Nishikawa (20). 
Flow Cytometry and CelISorting.  Cells  from the spleen, the bone 
marrow, and the peritoneal cavity of mice were applied to Ficoll- 
Hypaque gradient centrifugation, and mononuclear calls enriched 
at the interface layer were used for flow cytometric analysis.  Single 
cell suspensions  were stained with appropriate antibodies, and ana- 
lyzed by FACScan  |  (Becton Dickinson & Co., Mountain View, 
CA) after exclusion  of  dead cells  by propidium iodide gating. Two- 
color staining of the cells with anti-B220 and anti-IgM antibodies 
was done as described  by Okamoto et al. (5). The amounts of au- 
toantibodies on erythrocytes were measured with flow cytometry 
using FITC goat anti-mouse IgM antibody (Cappd Laboratories, 
Malvern, PA) (5). Mean fluorescence  intensities (MHs) were ob- 
tained with the equation: MFI  =  10  Ix/zs2) (X  =  mean fluores- 
cence). Bone marrow cells from El~-bcl-2 transgenic mice were 
stained with anti-B220 (6B2) and anti-slgM antibodies. B220  + 
sIgM- and B220" sIgM + cells were sorted using FACStar  |  and 
the consort 30 program (Be, ton Dickinson & Co.). 
Polymerase Chain Reaction.  %tal cytoplasmic  RNA was extracted 
from  10  s splenocytes or bone  marrow cells of mice using  the 
RNase inhibitor vanadyl ribonucleotide complex (21). Random 
primed first strand cDNA synthesis was carried out using abelson 
murine leukemia virus (AMV) reverse transcriptase (Seikagaku 
Kogyo, Tokyo,  Japan). The cDNA was amplified  with human bcl-2 
primers;  5'  primer, ACACGCCCCATACAGCCGCAT and  3' 
primer, CAAGCTCCCACCAGC~CCAAA  for 30 cycles on a 
DNA thermal cycler (Perkin Elmer Corp., Nowalk, CT). The ex- 
pected size of the amplified band is 522 bp. 
ELISA.  The numbers of antibody-producing cells in 105 cells 
of the spleen, the bone marrow, the lymph nodes, and the perito- 
neal cavity from mice at 8 wk of age were analyzed with enzyme- 
linked immunospot assay  using anti-idiotype antibody ($54) as de- 
scribed by Murakami et al. (10). 
Induction and Assay of  Peritoneal Cell Death.  8-wk-old  mice were 
injected intraperitoneously with 109 RBCs in 500 #1 of PBS. 12 h 
after injection, peritoneal ceils from each mouse were subjected 
to flow cytometry and DNA fragmentation assay. DNA was iso- 
lated from peritoneal cells as described by Ishida et al. (22). The 
sample was electrophoresed in a 2% agarose gel with TAE buffer 
(40 mM Tris-acetate, 1 mM ~, pH 8.0). DNA was subsequently 
visualized by ethidium bromide staining. 
Results 
Autoimmune Symptoms in Transgenic Mice Carrying bcl-2 and 
Anti-erythrocyte  Autoantibody  Genes.  To examine the effect 
of the bcl-2 gene on B cell tolerance,  we analyzed transgenic 
mice expressing both the 4C8 antierythrocyte autoantibody 
and the bcl-2 gene in B lineage cells (bcl-2  x  H  x  L mice). 
We assessed the incidence of anemia and the amounts of au- 
toantibodies produced by measuring hematocrit (Ht)  and 
quantitating autoantibodies bound to circulating erythrocytes 
ofS-wk-old bcl-2 x  H  x  L mice. As a control, we examined 
transgenic mice carrying only the H  and L chain genes for 
the antierythrocyte antibody (H  x  L mice) at the same age 
under the same breeding conditions. Both bcl-2  x  H  x  L 
and H  x  L mice showed wide variations of the Ht values 
and the amounts of autoantibodies on RBCs (Fig.  1, a and 
b).  The Ht value in each  transgenic mouse was inversely 
proportional to the amount of the autoantibody bound to 
erythrocytes, indicating that the autoantibodies are respon- 
sible for hemolytic anemia as previously shown for H  x  L 
mice (5). About one third of bcl-2  x  H  x  L mice showed 
Ht values <35%,  whereas all of the H  x  L mice showed 
Ht values >35%, indicating the enhanced occurrence of the 
autoimmune disease by introduction of the bet-2 transgene. 
This finding is also supported by the increased  amounts of 
the autoantibody bound to erythrocytes in bcl-2  x  H  x  L 
mice as compared with H  x  L mice. Nevertheless, two thirds 
ofH x  L mice and one third ofbcl-2  x  H  x  L mice showed 
neither anemia (Ht  <40%)  nor autoantibody production 
(MFI >50), indicating that self-reactive B cells are toterized 
at least in some individuals of bcl-2  x  H  x  L  mice as well 
asH  x  Lmice. 
To identify B cells responsible for the autoimmune disease 
manifested in two thirds of bcl-2  x  H  x  L mice, we com- 
pared the number of B cells in various lymphoid organs in 
severely  anemic  (Ht  <35%)  and nonanemic (Ht  >40%) 
bcl-2  x  H  x  L mice.  The numbers of B cells in the bone 
marrow and spleen of bcl-2  x  H  x  L mice were decreased 
to the same level regardless  of their Ht values as shown in 
H  x  L  mice  (10). We  next  examined  the  number  of 
autoantibody-producing cells in the spleen,  bone marrow, 
lymph nodes, and peritoneal cavity in bd-2  x  H  x  L mice. 
The number of antibody-producing cells in the peritoneal 
cavity of anemic bcl-2 x  H  x  L mice was markedly increased 
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Figure 1.  Hemolytic anemia in H  x  L and bcl-2 x  H  x  L mice. 
(a) Ht values ofH x L and bcl-2 x H  x L mice. (O, @)18 individuals 
of H  x L mice and 12 individuals of bcl-2 x H  x L mice, respectively. 
Ht value of each individual is indicated. (b) MFIs of H  x  L and kl-2 
x H  x L mice. The amounts of the autoantibody (IgM) bound to cir- 
culating erythrocytes were quantitated by staining with anti-lgM anti- 
body as described in Materials and Methods. The MFI of each H  x 
L (O) and bcl-2 x  H  x  L (O) mouse is indicated. All the mice used 
were maintained under the same conditions. 
as compared to nonanemic bcl-2  x  H  x  L  mice (Table  1). 
Regardless  of anemic  and  nonanemic  mice,  spleen,  bone 
marrow, and lymph nodes of bcl-2  x  H  x  L mice contained 
<10 autoantibody-producing cells per 10  s cell in agreement 
with the results on H  x  L mice (10). These results indicate 
that peritoneal Ly-1 B cells are responsible for hemolytic anemia 
in bcl-2 x  H  x  L mice as is the case for H  x  L mice (5, 10). 
Clonal Deletion of Bone Marrow B Cells in Anti-RBC Trans- 
genic Mice Is Not Inhibited  by bct-2.  To assess clonal deletion 
of self-reactive B cells, we measured the number of B cells 
in various organs.  We obtained cells  of the bone marrow, 
spleen,  and peritoneal  cavity from bcl-2  x  H  x  L  mice at 
8 wk of age and stained the cells with anti-B220 and anti- 
IgM antibodies. Subsequently, the cells were analyzed by flow 
cytometry. The cells from 8-wk-old transgenic mice carrying 
the bcl-2 gene alone (bcl-2 mice), both the bcl-2 and 4C8 H 
chain genes (bcl-2  x  H  mice), both the kl-2 gene and 4C8 
L chain genes (bcl-2  x  L mice),  and the bcl-2, H  chain for 
an anti-NP antibody and 4C8 L  chain genes (bcl-2  x  HNp 
x  L mice), were used as controls. The number of both bone 
marrow and spleen B cells increased in the presence of kl-2 
as shown before (23, 24), whereas the introduction of Ig H 
or L chain caused little or moderate reduction of the number 
of bone marrow and spleen B  cells in agreement with the 
previous report (5). The B cell number in the bone marrow 
of H  x  L mice showed a two- to three-fold decrease as com- 
pared with the mice with Ig H  or L chain transgene (Table 
2).  A  more marked decrease (5-10-fold) in the  number of 
B cells was observed in the spleen and the bone marrow of 
bcl-2  x  H  x  L  mice as compared with mice carrying bcl-2 
Table  1.  Localization of anti-RBC Antibody-producing Cells in Anemic  and Nonanemic bcl-2  x H x L  Mice 
Frequency of anti-RBC antibody-producing cells*  ( x 10 -s) 
Inguinal 
Symptom  Spleen  Bone marrow  lymph node  Peritoneum 
Severe anemia*  <10  <10  <10  221  _+  25 u 
Nonanemia$  <10  <10  <10  24.7  +  5.5  II 
* Numbers of antierythrocyte antibody-producing cells measured by enzyme-linked immunospot assay. 
* bcl-2 x H x L mice whose Ht values were <35%. 
S kl-2 x H x L mice whose Ht values were >40%. 
LI Mean _+ SD of three individuals. 
Table  2.  Percentage  of B Lymphocytes in  Various Organs of Transgenic Mice Carrying Either Ig  Chain or bcl-2 Gene 
Nontransgenic 
littermate  L chain  H  chain  H x L  bcl-2  kl-2 x L  bcl-2 x H  bcl-2 x H x L 
Spleen  51.2  _+  5.5  30.2  _+  3.2  36.0  _+  9.2  3.4  +  1.9  83.0  40.9  72.6  3.4  _+  1.7 
Bone marrow  14.4  _+  2.8  6.6  +  1.9  10.1  _+  2.1  3.1  _+  2.1  75.4  35.9  63.3  6.2  +  2.1 
Peritoneal cavity  42.5  _+  5.3  40.9  41.8  36.7  +  2.8  79.7  76.8  75.8  35.3  _+  7.4 
Numbers with  +_  SD are from three mice and the other numbers are one representative value. 
1249  Nisitani  et al. and either Ig H  or L chain of 4C8,  or mice carrying bcl-2 
and IgM incapable  of reacting with erythrocytes (Fig. 2 and 
Table 2). These results indicate that bone marrow B cells are 
eliminated and failed  to generate peripheral  B cells in bcl-2 
￿  H  x  LaswellasH  x  Lmice. 
To show that maintenance  of clonal deletion of self-reactive 
B cells in the bone marrow in bcl-2  x  H  x  L mice is not 
due to lack of bcl-2 expression in immature B cells, we sorted 
pre-B cells (B220 + slgM-) and B cells (B220 + sIgM hi) from 
the bone marrow of bcl-2 mice (Fig. 3 a) and examined bcI-2 
expression in these populations by reverse PCR. Splenocytes 
of bcl-2 mice were used as a positive control. The bcl-2 gene 
was amplified from cDNA of both pre-B and B cells in bcl-2 
mice (Fig. 3 b). In contrast, the bcl-2 gene was not amplified 
in the absence of reverse transcriptase, indicating that genomic 
DNA was not contaminated in the cDNA  samples.  Taken 
together, the bcl-2 gene product does not inhibit clonal dele- 
tion of self-reactive  immature B cells in the bone marrow. 
In bcb2  x  H  x  L mice, a normal number ofLy-1 B cells 
(B220 ~~ sIgMhi),  but only few conventional B  cells (B220 hi 
slgM 1~  were observed in the peritoneal cavities  (Fig.  2 c), 
showing that conventional but not Ly-1 B cells are deleted 
in the peritoneal cavity of bcl.2  x  H  x  L mice as is the case 
for peritoneal B cells in H  x  L mice (10). The number of 
conventional B cells in the peritoneal cavity,  in contrast, is 
markedly larger  in bcl-2  x  HNp  x  L,  bcl-2  x  H,  bcl-2  x 
L, and bcl-2 mice than in normal mice. Conventional but not 
Ly-1  B  cells appear to expand in the presence  of the bcl-2 
gene product when antigen-specific clonal deletion does not 
take  place. 
The bcl-2 Gene Product Inhibits Antigen-induced Apoptosis in 
Peritoneal Ly-I B Cells.  In H  x  L mice, the intraperitoneal 
injection of RBCs almost completely eliminates peritoneal 
Ly-1 B cells by inducing apoptotic cell death (10). We asked 
if the bcl-2 gene product inhibits the antigen-induced apop- 
toffs of peritoneal Ly-1  B cells by intraperitoneal injection 
of RBCs.  We injected various  amounts  of RBCs into the 
peritoneal cavity of bcl-2  x  H  x  L, H  x  L mice and non- 
transgenic littermates  at 8 wk of age.  12 h after injection, 
we collected the peritoneal cells and measured  the number 
of peritoneal B cells by two-color staining with the anti-B220 
and anti-IgM antibodies,  followed by flow cytometry anal- 
ysis. Although peritoneal Ly-1 B cells were almost completely 
eliminated  in  H  x  L  mice  with  the  injection  of 10 ~ of 
RBCs,  little reduction in the number of peritoneal Ly-1  B 
cells was observed in both bcl-2  x  H  x  L mice and non- 
transgenic  littermates  even with injection of 10  ~ RBCs (Fig. 
4 a).  These results  indicate that self-reactive  mature B cells 
were no longer eliminated upon interaction with self-antigens 




HxL  bcl-~HxL 
I  .  .'  3 
￿9  ,  .,  ..  ;:~;:. 
,  .'~ .7"  ,.  "  .'  ",,  ".',  .:" 
.~=~...,--~,; --  ~..,_:  .......  ;.,~,..,-.,,..:.:. ............. 
~ :'  )!~t~,.':'.: :::.:.... 
,.,  .  :.  ~'.-.~!?~. 
.: ..~ji..'h,,  ....?': '  ￿9  - ,. :~-  ...... 
,.'  ,:~. 
￿9  I'"<.~  "."~'L :~" 
i 
,  7 
q'::..  ,.  ~:~ 
~,#;'~;~..,..,:.,..~: 
~,~i~..:§  ￿9 
'  ~"  "  I  ~.;~  ,.:;~;'~t;~: 
..:.:,.'.~b~;.~;;,;  ..  :..  ,.....  ,,~;~  :. 
,.,  ..,~..,.~ .....  .~;~-  .....  ,  "  ~,~.,  ...... 
,."  ~,.,,-..  :;.'..;,.;..-,,,;,..---.,.',...--,  ,..o'"'-  ,.,",,-,,.,  '.-,,.v  .... 
bcl-2XHNpXL 
￿9 ~:,~' 
:..;,:.  5 2 
i 
.........  i  :.::~:  ~  ,  ~:  .~.  4~  ...... 
','~  "i:.  ~:~i': 
"'?:  :';":"  :.i'.!;i~!':.! 
bc/-~H  bc/-,~L 
',  ,  . 
,  73  ,  41  ' 
',  :" :?'.::i:~ % 
￿9 ~.!:,..~  i  ..  - '-h,'r 
=. 
: ?::{i:,2.. 
.=  . 
~4~4"""is 




,  ,..~ ,,, 
￿9 .  i,;,~:[:.'~:):  .  ........ 
'  ~,,:;~i:~i  :  ::~'  I  !  ::~:~::'  ,  :::~i~li:  I  .i:; f; ~!;~  77  i  "; 'i:(;~s I:'~I  80 
￿9  "  ~:~,~t.~  }  ".~1;.:  ,  ..:';yfc. 
B220 
Figure  2.  Flow cytometry analysis of B cells in the H  x  L, bcl-2  x  H  ￿  L,  bcl-2  x  HNV  x  L,  bcl-2  ￿  H,  bcl-2  ￿  L, and bcl-2 mice. Cells from 
the spleen (a), the bone marrow (b), and the peritoneal cavity (c) of transgenic mice at 8 wk of age were collected, washed with PBS twice, and stained 
with the anti-B220 (6B2) antibody,  followed by staining  with FITC-labeled  mouse anti-rat-K chain  antibody and PE-labeled  goat anti-mouse IgM 
antibody￿9 The cells were analyzed by FACScan|  fluorescent  four-quadrant,  two-color plots were generated with logarithmic amplification  of fluores- 
cence emitted by single viable cells. Dots and numbers (%) in the fluorescence windows refer to the cells in the lymphocyte gate as defined by light scatter￿9 
1250  bcl-2 Abrogates  Peripheral Tolerance but Not Central  Tolerance Figure  3.  (a) Cells sorted from 
the bone marrow of kl-2 nfice and 
used for reverse PCR. Cells from 
bone marrow of kl-2 mice were 
stained  with  anti-B220  (6B2) 
and  anti-IgM  antibodies  and 
sorted with a cell sorter. Compart- 
ments A  and B indicate  B220 + 
slgM  hl cells and  B220 +  slgM- 
cells, respectively. (b) bcl-2 trans- 
cripts from bone marrow cells of 
C57BL/6  mice  (lane  I),  pre-B 
(B220 + slgM-) cells and B220 + 
slgM  hi  B  cells  sorted  from  the 
bone marrow (lanes 2 and 3), and 
splenocytes (lane 4) of kl-2 mice. 
mRNA for bcl-2 was detected by 
reverse PCR and the expected size 
is indicated  by an  arrow in  the 
figure. 
toneal Ly-1 B cells was found in both anemic and nonanemic 
bcl-2  x  H  x  L  mice (data not  shown). 
To  address  the question whether bcl-2 inhibits  antigen- 
induced apoptosis  of Ly-1  B  cells  even by longer antigen 
exposure, we injected 109 RBCs per day for 7 d  intraperi- 
toneously into the bcl-2  x  H  x  L  mice, H  x  L mice, and 
nontransgenic  littermates.  Elimination  of peritoneal  self- 
reactive B cells was not observed in bcl-2  x  H  x  L mice, 
suggesting that  bcl-2 protected the peritoneal B cells from 
clonal deletion under sustaining exposure to antigens. Fur- 
thermore, DNA fragmentation was observed in peritoneal 
cells of RBC-injected H  x  L mice but not in those of bcl-2 
x  H  x  L mice nor nontransgenic littermates which received 
the same treatment (Fig. 5). In summary, these results clearly 
indicate that the bcl-2 gene product inhibits antigen-induced 
apoptosis of peritoneal Ly-1  B cells. 
Discussion 
Elimination of self-reactive B cells is observed in both im- 
mature bone marrow B cells and mature peritoneal Ly-1 B 
cells in H  x  L mice (5,  10). By taking advantage of these 
mice, we assessed the effect of the bcl-2 gene product on elimi- 
nation of self-reactive B cells at the immature and mature 
stage.  As is the case for H  x  L  mice, self-reactive B cells 
of bcl-2  x  H  x  L mice were eliminated at the stage of bone 
marrow immature B cells despite bcl-2 expression in these 
cells. However, peritoneal Ly-1 B cells were no longer elimi- 
nated upon intraperitoneal injection of 109 RBCs for 7 d in 
bcl-2  x  H  x  L  mice,  whereas  a  single  injection  of 107 
RBCs  eliminated almost all the peritoneal Ly-1  B  cells in 
H  x  L mice. Expression of bcl-2 in B cells has been shown 
to increase the number of B cells and the amount of anti- 
body production (23, 24). In bd-2  x  H  x  L mice, however, 
neither the number of peritoneal B cells nor antibody produc- 
tion increased as compared with H  x  L mice, although anti- 
body production was elevated in anemic mice. Thus, RBC 
injected into the peritoneal cavity of nonanemic bcl-2  x  H 
x  L mice should interact with B  cells  as effectively as in 
H  x  L mice (10), nonetheless failed to induce apoptosis even 
when we used 100 times more RBCs required for elimina- 
tion orB cells in H  x  L mice. These results strongly suggest 
that  kl-2  blocks  antigen-induced  apoptosis  of peritoneal 
Ly-1 B cells. Abrogation of apoptosis by kl-2 is not restricted 
to Ly-1 B cells.  Indeed, constitutive bcl-2 expression blocks 
apoptosis of conventional as well as Ly-1 B cells in peritoneal 
cavity upon slg cross-linking by anti-Ig injection (Tsubata 
T., M. Muralcami, and T. Honjo, manuscript submitted for 
publication). Although it is not clear how many RBCs are 
required to interact with bone marrow B cells and how long 
it takes for bone marrow B cells to be eliminated, peritoneal 
B cells may be exposed to more RBCs for a longer period 
than B cells by the 7-d consecutive injection of 109 RBCs, 
which exceeds all the RBCs in the murine bone marrow of 
a single mouse. This treatment, nonetheless, failed to induce 
apoptosis of peritoneal Ly-1 B cells in kl-2  x  H  x  L mice, 
whereas immature self-reactive B cells in the bone marrow 
are eliminated in these mice. It is therefore most likely that 
bd-2 has different effects on antigen-induced elimination of 
bone marrow immature and peritoneal Ly-1  B cells. 
In contrast to our results, Hartley et al. (25) demonstrated 
that the number of immature B cells increased in the bone 
marrow and spleen in the host mice expressing the hen egg 
lysozyme (HEL) gene which were reconstituted with bone 
marrow cells of anti-HEL antibody transgenic mice bearing 
the bd-2 transgene. Different results in the two systems could 
be due in part to the difference in  the expression levels of 
self-antigens in the bone marrow and the binding affinities 
between antigens and antibodies. Moreover, irradiated spleen 
is shown to secrete cytokines that support growth of imma- 
ture hemopoietic precursors (26).  Such a microenvironment 
may allow expansion of immature B cells expressing kl-2 in 
the spleen as well as bone marrow of irradiated host. 
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Figure  4.  (a) Flow cytometry analysis of peritoneal cells of H  x  L,  bcl-2  x  H  x  L  mice and nontransgenic  littermates  after injection  of various 
amounts  of RBC.  RBCs (109,  10  n, 10;') in 500/~1 PBS were injected intraperitoneously  to 8-wk-old mice.  After 12 h, mice were killed and peritoneal 
cells were collected.  Ceils were subjected to flow cytometry  as described in the legend  to Fig.  2.  Cells from nontreated  mice were used as controls. 
(b) Flow cytometry  analysis of peritoneal cells of bcl.2  x  H  x  L  mice  after injection  of 109 P,.BCs  per day for seven consecutive  days.  RBCs  (109) 
in 500 #1 of PBS were injected  intraperitoneously  into  12-wk-otd  bcl-2  x  H  x  L  mice (day 0-day 6).  On day 7,  peritoneal cells of the mice were 
analyzed using flow cytometry as described above.  Peritoneal cells of nontreated bcl-2  x  H  x  L mice at the same age were analyzed in the same way 
as controls.  Percentage  of B220*  sIgM +  B  calls is indicated  in each compartment. 
1252  bcl-2 Abrogates  Peripheral  Tolerance but Not  Central  Tolerance Figure 5.  DNA  fragmentation 
assay of peritoneal cells from RBC- 
injected transgenic mice. Nontrans- 
genic  littermates  (lane  I), H  x L mice 
(lane 2), and bd-2 x H  x L mice  (lane 
3)  were injected with  10  9 RBCs. 
12 h after injection, peritoneal cells 
were collected and DNA extracted 
was electrophoresed  in a 2% agarose 
gel. Note that DNA fragmentation 
is observed  only in DNA from RBC- 
injected H  x  L mice. 
Although both immature and mature self-reactive B cells 
have been shown to be clonally deleted by signaling via slg 
receptors upon interaction with self-antigens (10, 11), mech- 
anisms for antigen-induced elimination of self-reactive B cells 
appear to be different in immature and mature B cells. This 
could be  due to  the fact that  signaling  pathways via  slg 
receptors are different between the two stages of B cells (11, 
12).  Different responses to self-antigen stimulation by im- 
mature and mature B cells were also shown by recent studies 
on autoantibody transgenic mice (27, 28) demonstrating that 
cross-linking of slg induced replacement of the Ig r  chain 
in  self-reactive immature B  cells,  not  in  mature  B  cells. 
Moreover, maturation arrest but not antigen-induced apop- 
tosis might be involved in clonal deletion of immature B cells 
(25).  Mature B cells are able to respond to foreign antigens, 
suggesting that stimulation with foreign antigens may acti- 
vate the machinery rescuing slg-mediated apoptosis of ma- 
ture B cells. We have shown that signaling through slg does 
not kill but activates normal B cells in the peritoneal cavity 
in bd-2 transgenic mice (Tsubata et al., manuscript submitted 
for publication). Presumably bd-2 may play a role in the rescue 
machinery of mature B cells from slg-mediated apoptosis. 
Hemolytic anemia was more frequent and severe in bcl-2 
x  H  x  L mice than in H  x  L mice. Moreover, the severity 
of hemolytic anemia is proportional to the number of au- 
toantibody producing cells in the peritoneal cavity, in agree- 
ment with the finding with H  x  L mice (10). These findings 
indicate that peritoneal Ly-1 B cells are responsible for hemo- 
lytic anemia in bcl-2 x  H  x  L mice as well as H  x  L mice. 
Since the self-reactive B cells in the peritoneal cavity are anyway 
shielded from the self-antigens (RBCs),  it is unlikely that 
the abrogation of peripheral clonal deletion of self-reactive 
B cells is responsible for the aggravation of hemolytic anemia 
in  bcl-2  x  H  x  L  mice.  Rather,  prolonged  survival  for 
antibody-producing cells might aggravate hemolytic anemia 
in  bd-2  x  H  x  L  mice. 
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